Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer

Clinical Breast Cancer

Volumn 7, Issue 11, 2007, Pages 861-866

  Paridaens, Robert ^a,f   Dirix, Luc ^b   Dumez, Herlinde ^a   Prové, Annemie ^b   Wildiers, Hans ^a   Alvarez, Ana ^c   Oliveira, Celia Tosello ^d   Latz, Jane ^e   Simms, Lorinda ^e   Melemed, Allen ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Oncology Centre of Antwerp   (Belgium)

^c Instituto Angel Roffo   (Argentina)

^d Instituto Brasileiro de Controle do Cancer   (Brazil)

^e ELI LILLY AND COMPANY   (United States)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Dose reduction; Left ventricular ejection fraction; Neutropenia; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CYANOCOBALAMIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; FOLIC ACID; PEMETREXED;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CARDIOTOXICITY; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DIVERTICULITIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HEART EJECTION FRACTION; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPONATREMIA; INFECTION; LEUKOPENIA; LIVER FUNCTION; LYMPHOCYTOPENIA; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PARESIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRURITUS; RASH; SIDE EFFECT; SKIN INFECTION; THROMBOCYTOPENIA; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VOMITING;

EID: 38049072784     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.n.051     Document Type: Article

References (26)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24:2137-50.
2. Hamilton A, Hortobagyi G. Chemotherapy: what progress in the last 5 years? J Clin Oncol 2005; 23:1760-75.
3. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993; 19:197-228.
4. Findlay BP, Walker-Dilks C. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1998; 2:140-6.
5. Feher O, Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol 2005; 16:899-908.
6. French Epirubicin Study Group. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 1991; 9:305-12.
7. Lawton PA, Spittle MF, Ostrowski MJ, et al. A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma. Clin Oncol (R Coll Radiol) 1993; 5:80-4.
8. Bastholt L, Dalmark M, Gjedde SB, et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 1996; 14:1146-55.
9. Mendelsohn LG, Shih C, Chen VJ, et al. Enzyme inhibition, polyglutamation and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999; 26:42-7.
10. Adjei AA. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther 2003; 3:145-56.
11. Dittrich C. Use of pemetrexed in breast cancer. Semin Oncol 2006; 33(suppl 9):S24-8.
12. Martin M. Clinical experience with pemetrexed in breast cancer. Semin Oncol 2006; 33(suppl 2):S15-8.
13. Teicher BA, Chen V, Shih C, et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 2000; 6:1016-23.
14. Schultz RM, Dempsey JA. Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res 2001; 21:3209-14.
15. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82:1109-18.
16. Green W, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10:239-53.
17. Latz JE, Chaudhary A, Ghosh A, et al. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 2006; 57:401-11.
18. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143-51.
19. Paridaens R, Dirix L, Dumez H, et al. Pemetrexed (Alimta®) and epirubicin in patients with locally advanced or metastatic breast cancer: a phase I study. Breast Cancer Res Treat 2005; 90:214 (Abstract 5068).
20. Garin A, Manikhas A, Biakhov M, et al. A phase II study of pemetrexed plus carboplatin as first-line therapy of patients with locally advanced (LA) or metastatic breast cancer (MBC): preliminary results. J Clin Oncol 2005; 23(16 suppl):51s (Abstract 694).
21. Ma CX, Steen P, Rowland KM, et al. A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study. Ann Oncol 2006; 17:226-31.
22. Dittrich C, Petruzelka L, Vodvarka P, et al. A phase I study of pemetrexed (Alimta) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. Clin Cancer Res 2006; 12:7071-8.
23. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 2000; 18:724-33.
24. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005; 10(suppl 3):20-9.
25. Llombart-Cussac A, Martin M, Harbeck N, et al. A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res 2007; 13:3652-9.
26. Hughes AN, Lind M, Azzabi A, et al. A phase I dose escalation study of doxorubicin in combination with pemetrexed (Alimta®, multitargeted antifolate). Breast Cancer Res Treat 2001; 69:286 (Abstract 438).